Home » Topics » Regulatory » EMA

EMA
RSS

Novartis announces CHMP opinion on Signifor

Jan. 23, 2012

CHMP issues opinion on Folotyn

Jan. 23, 2012

EMA validates MAA for single-tablet HIV-1 therapy

Dec. 23, 2011

Roche's Zelboraf receives CHMP opinion

Dec. 21, 2011

CHMP issues recommendation on marketing authorization Esmya

Dec. 21, 2011

Vertex gives update on Kalydeco NDA and MAA

Dec. 20, 2011

EMA approves combination antimalarial drug Eurartesim

Dec. 2, 2011

EMA committee recommends approval of new indication for Herceptin

Nov. 23, 2011

CHMP recommends variation to marketing terms for Nevanac

Nov. 22, 2011

EMA to begin review of Pfizer's tofacitinib MAA for rheumatoid arthritis

Nov. 22, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...